A61K 39/1045
Moraxella
Official title: {Moraxella}
A61K39/1045 (Moraxella) appears on 60 US grants and 88 published applications in this corpus.
Search patents in A61K- Granted patents
- 60
- Published applications
- 88
- Assignees
- 44
- Inventors
- 176
- Latest grant
- 18 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 2 |
| 2005 | 1 | 2 |
| 2006 | 1 | 7 |
| 2007 | 1 | 4 |
| 2008 | 1 | 2 |
| 2009 | 2 | 2 |
| 2010 | 3 | 2 |
| 2011 | 0 | 5 |
| 2012 | 3 | 5 |
| 2013 | 1 | 4 |
| 2014 | 3 | 1 |
| 2015 | 1 | 3 |
| 2016 | 2 | 6 |
| 2017 | 4 | 7 |
| 2018 | 10 | 7 |
| 2019 | 5 | 4 |
| 2020 | 5 | 8 |
| 2021 | 3 | 2 |
| 2022 | 1 | 4 |
| 2023 | 2 | 3 |
| 2024 | 0 | 2 |
| 2025 | 2 | 3 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Acinetobacter baumannii immunogenic protein and composition and application thereof18 Feb 2025US 12,227,545 B2Chengdu Olymvax Biopharmaceuticals Inc.
- Vaccine delivery method7 Jan 2025US 12,186,390 B2University of Georgia Research Foundation, Inc.
- Methods of boosting immune responses15 Aug 2023US 11,723,966 B2Glaxosmithkline Biologicals SA
- Compositions and methods for a multi-adjuvant only approach to immunoprophylaxis for preventing infections13 Jun 2023US 11,672,857 B2University of Southern California
- Vaccine delivery method13 Dec 2022US 11,524,072 B2University of Georgia Research Foundation, Inc.
- Inhaled adenovirus vector vaccine, preparation method therefor and use thereof8 Oct 2026US 2026/0306605 A1Cansino Biologics Inc.
- Acinetobacter vaccine and method of use thereof9 Jul 2026US 2026/0191944 A1Washington University
- Topical nasal pharmaceutical composition for the treatment and prophylaxis of chronic rhinosinusitis (crs)23 Apr 2026US 2026/0108489 A1
- Immunogenic compositions and methods for reducing transmission of pathogens2 Oct 2025US 2025/0302937 A1St. Jude Children?S Research Hospital
- Continuous process for vaccine production22 May 2025US 2025/0161895 A1Glaxosmithkline Biologicals SA
Most cited
By later US patents
- Polyvalent shipping fever vaccine42US 4,167,560 ATexas Vet Lab, Inc. · 1979
- Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability24US 7,608,278 B2Wyeth · 2009
- Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans14US 6,685,949 B1The United States of America as represented by the Department of Health and Human Services · 2004
- Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB- Neisseria meningitidis14US 7,838,014 B2Glaxosmithkline Biologicals SA · 2010
- Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation13US 4,789,544 AMidcon Labs. Inc. · 1988